Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02772003 · ClinicalTrials.gov registry record · Phase 1

DNA Vaccine Therapy in Treating Patients With Chronic Hepatitis C Virus Infection

A Phase 1 study of Hepatocellular Carcinoma and Hepatitis C Infection, sponsored by National Cancer Institute (NCI).

Active
Registry status
Phase 1
Development phase
33
Enrollment target
5
Study locations

NCT02772003 is a Phase 1 study of Hepatocellular Carcinoma and Hepatitis C Infection that is active but no longer recruiting, run by National Cancer Institute (NCI). The registered enrollment target is 33 participants, below the 257-participant average among 145 other Hepatocellular Carcinoma trials with a reported enrollment target (87% lower). The trial reports 5 study locations across 5 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02772003, a Phase 1 study of Hepatocellular Carcinoma and Hepatitis C Infection, is active but no longer recruiting, sponsored by National Cancer Institute (NCI).

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
33 participants
Enrollment target
5
Study locations

Study Summary

This phase I trial studies the side effects and best dose of deoxyribonucleic acid (DNA) vaccine therapy in treating patients with hepatitis C virus (HCV) infection that persists or progresses over a long period of time. Vaccines made from DNA may help the body build an effective immune response to kill cancer cells that express HCV infection.

Conditions Studied

Hepatocellular Carcinoma Hepatitis C Infection Chronic Hepatitis

Interventions

  • OTHER Quality-of-Life Assessment
  • OTHER Laboratory Biomarker Analysis
  • BIOLOGICAL Electroporation-Mediated Plasmid DNA Vaccine Therapy
  • BIOLOGICAL HCV DNA Vaccine INO-8000
  • BIOLOGICAL Rocakinogene Sifuplasmid

Study Locations (5)

Florida

  • Mayo Clinic in Florida - Jacksonville

Minnesota

  • Mayo Clinic in Rochester - Rochester

Ohio

  • Case Western Reserve University - Cleveland

Pennsylvania

  • Temple University Hospital - Philadelphia

Other

  • University of Puerto Rico - San Juan

Trial Details

FieldValue
Enrollment Target 33 participants
Start Date 2016-06-06
Est. Completion 2027-03-09
Phase Phase 1

Sponsor

National Cancer Institute (NCI)

3,257 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT02772003

The ClinicalTrials.gov registry entry for NCT02772003 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 33 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 257-participant average among 145 other Hepatocellular Carcinoma trials with a reported enrollment target (87% lower). The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Hepatocellular Carcinoma appearing as the primary indexed condition, and to 5 interventions - of which Quality-of-Life Assessment is the first listed.

NCT02772003 reports 5 study locations spanning 5 distinct geographic areas - top geographies include Florida, Minnesota, Ohio.

Frequently Asked Questions

What is clinical trial NCT02772003 about?

NCT02772003 is a clinical study titled "DNA Vaccine Therapy in Treating Patients With Chronic Hepatitis C Virus Infection". This phase I trial studies the side effects and best dose of deoxyribonucleic acid (DNA) vaccine therapy in treating patients with hepatitis C virus (HCV) infection that persists or progresses over a long period of time. Vaccines made from DNA may help the body build an effective immune response to ...

What is the current status of trial NCT02772003?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 33 participants. The study started on 2016-06-06. Estimated completion is 2027-03-09.

What conditions does trial NCT02772003 study?

This clinical trial studies the following conditions: Hepatocellular Carcinoma, Hepatitis C Infection, Chronic Hepatitis.

What interventions are being tested in trial NCT02772003?

The interventions under investigation include: Quality-of-Life Assessment (OTHER), Laboratory Biomarker Analysis (OTHER), Electroporation-Mediated Plasmid DNA Vaccine Therapy (BIOLOGICAL), HCV DNA Vaccine INO-8000 (BIOLOGICAL), Rocakinogene Sifuplasmid (BIOLOGICAL).

Who is sponsoring clinical trial NCT02772003?

This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02772003 being conducted?

This trial has 5 study locations across Florida, Minnesota, Ohio, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Hepatocellular Carcinoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Hepatocellular Carcinoma

All registered trials for this condition

Hepatitis C Infection

All registered trials for this condition

Florida

All trials with a study site in Florida

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.